Biora Therapeutics Announces New Patents For NaviCap Targeted Oral Delivery Platform
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics has been granted several new patents by the European Patent Office and the U.S. Patent and Trademark Office. These patents are related to the treatment of diseases of the gastrointestinal tract using various inhibitors and agents released using an ingestible device.
June 28, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biora Therapeutics has secured multiple new patents for its NaviCap Targeted Oral Delivery Platform. This could potentially lead to new product developments and revenue streams.
The acquisition of new patents is a positive development for Biora Therapeutics. It not only strengthens the company's intellectual property portfolio but also opens up potential new avenues for product development and revenue generation. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100